Oxemiatm Is A Hypoxia-Inducible Factor-Prolyl Hydroxylase (Hif-Ph) Inhibitor That Is Taken Orally. In The Dream-D And Dream-Nd Phase Iii Clinical Trials, Desidustat Met Its Primary Endpoints For Haemoglobin Improvement And Demonstrated A Good Safety Profile, As Well As Down Regulation Of Hepcidin, Improved Iron Mobilisation, And Ldl-C Reduction In Ckd Patients Zydus Lifesciences Announced That The Drug Controller General Of India (Dcgi) Has Accepted Its New Drug Application (Nda) For Oxemia (Desidustat), A First-Ofits-Kind Oral Medication For Anaemia Caused By Chronic Kidney Disease.
